• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Anthony Fauci, 100 Days Into the Biden Administration, Is Finally Getting to Do His Job
When Dr. Anthony Fauci arrived at 1600 Pennsylvania Ave. for his first White House press briefing under the new Biden Administration, he could see things would be different. It was the day after the Inauguration, and President Joe Biden was eager to get the country’s COVID-19 response back on track. Five minutes before he addressed the public, Fauci spoke with the new President. “He said, ‘I want you to just go and tell the science, explain to people that if we make mistakes, we’re going to fix the mistakes and we’re not going to dwell on the mistakes. Let science be communicated to the public...
Source: TIME: Health - May 18, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Phase 1 Randomized Placebo-Controlled Study in Healthy Adult Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate – A Potential Treatment for COVID-19
The airways and lungs are the primary sites of SARS-CoV-2 entry, replication, and damage, so there is reason to administer drugs to these regions. Oral hydroxychloroquine (oHCQ) has produced mixed results in COVID-19, despite reported antiviral activity in vitro (EC50=0.72-119 μM). We tested the hypothesis that aerosolized HCQ sulfate (aHCQ) tolerably, safely, and rapidly achieves high respiratory tissue concentrations, while minimizing systemic toxicity.
Source: Journal of Allergy and Clinical Immunology - February 1, 2021 Category: Allergy & Immunology Authors: Ohad Bentur, Richard Hutt, Donna Brassil, Per B äckman, Igor Gonda, Homer Boushey, B. Cahrous, Barry Coller, Robert MacArthur Source Type: research

Hydroxychloroquine and COVID-19: a Rheumatologist ’s Take on the Lessons Learned
AbstractPurpose of ReviewTold from the viewpoint of rheumatologists, this review tells the story of hydroxychloroquine and its swift ascent to become a household name as a therapeutic strategy against the novel SARS-CoV-2 virus. This review describes the history, mechanisms, pharmacokinetics, therapeutic applications, and safety profile of hydroxychloroquine as an immunomodulatory and antiviral agent. It also summarizes the major studies that launched and assessed the use of hydroxychloroquine against COVID-19 infection.Recent FindingsMore recent literature calls into question the long-held dogma that endolysosomal alkalin...
Source: Current Allergy and Asthma Reports - January 21, 2021 Category: Allergy & Immunology Source Type: research

What the Conflicting Results on Promising COVID-19 Drug Remdesivir Really Mean
Treating any infectious disease is a high wire act—doctors must balance the risks and benefits of therapies with the risks of the disease. And those stakes are even higher for a new disease that doesn’t yet have a playbook for physicians to follow. This summer, the U.S. Food and Drug Administration gave the drug remdesivir emergency use authorization for treating any patients hospitalized with COVID-19. But on Oct.15, researchers working on the World Health Organization’s (WHO) Solidarity trial published a preliminary report showing that nearly 3,000 people receiving the treatment were not more likely to ...
Source: TIME: Health - October 19, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Vaccines, Antibodies and Drug Libraries. The Possible COVID-19 Treatments Researchers Are Excited About
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19. It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

All Your Coronavirus Questions, Answered
One of the worst symptoms of any plague is uncertainty—who it will strike, when it will end, why it began. Merely understanding a pandemic does not stop it, but an informed public can help curb its impact and slow its spread. It can also provide a certain ease of mind in a decidedly uneasy time. Here are some of the most frequently asked questions about the COVID-19 pandemic from TIME’s readers, along with the best and most current answers science can provide. A note about our sourcing: While there are many, many studies underway investigating COVID-19 and SARS-CoV-19, the novel coronavirus that causes the illn...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: TIME Staff Tags: Uncategorized COVID-19 Explainer Source Type: news

President Trump Called Hydroxychloroquine a ‘Game Changer,’ But Experts Warn Against Self-Medicating With the Drug. Here’s What You Need to Know
After President Trump, late last week, expressed great confidence in the promise of a new COVID-19 therapy that combines two existing prescription medications, supplies of these two drugs rapidly began disappearing from pharmacy shelves. The U.S. Food and Drug Administration allowed an Indian company previously restricted from importing drug products into the US to now start manufacturing one of the drugs. And U.S. plants began gearing up to produce enough to meet the surge in demand. But in those few days, a few people who began self medicating with the drugs in an effort to prevent COVID-19 have died, and others have bee...
Source: TIME: Health - March 24, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Hydroxychloroquine Not Beneficial for SARS - CoV - 2 Preexposure Prophylaxis
No clinical benefit seen versus placebo for hospital - based health care workers exposed to patients with COVID - 19
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Cardiology, Dermatology, Endocrinology, Family Medicine, Geriatrics, Gastroenterology, Gynecology, Infections, AIDS, Internal Medicine, Allergy, Critical Care, Emergency Medicine, Nephrology, Neurology, Nursing, Oncology, Ophthalmology, Orthopedics, ENT, Source Type: news